

10/595,444

ISTRY' ENTERED AT 17:48:52 ON 16 DEC 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 DEC 2009 HIGHEST RN 1197459-30-5  
DICTIONARY FILE UPDATES: 15 DEC 2009 HIGHEST RN 1197459-30-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10595444.str

L7 STRUCTURE UPLOADED

=> s 17 sss sam

SAMPLE SEARCH INITIATED 17:49:27 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 4061 TO ITERATE

49.2% PROCESSED 2000 ITERATIONS 2 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 77398 TO 85042  
PROJECTED ANSWERS: 2 TO 201

L8 2 SEA SSS SAM L7

=> s 17 sss full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 185.40 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 17:49:46 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 81209 TO ITERATE

100.0% PROCESSED 81209 ITERATIONS 76 ANSWERS  
SEARCH TIME: 00.00.01

L9 76 SEA SSS FUL L7

10/923,271

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

186.36

429.28

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-7.38

FILE 'CAPLUS' ENTERED AT 17:49:53 ON 16 DEC 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Dec 2009 VOL 151 ISS 25

FILE LAST UPDATED: 15 Dec 2009 (20091215/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 19

L10 1 L9

=> d ibib abs hitstr

THE ESTIMATED COST FOR THIS REQUEST IS 5.64 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:429389 CAPLUS

DOCUMENT NUMBER: 142:481826

TITLE: Preparation of Phenethanolamine derivatives as selective  $\beta$ 2-adrenoreceptor agonists

INVENTOR(S): Biggadike, Keith

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 98 pp.



CODEN: PIXXD2

10/923,271

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005044787	A1	20050519	WO 2004-EP11963	20041021
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1675821	A1	20060705	EP 2004-790756	20041021
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007509852	T	20070419	JP 2006-536055	20041021
US 20070135490	A1	20070614	US 2007-595444	20070223
PRIORITY APPLN. INFO.:			GB 2003-24886	A 20031024
			WO 2004-EP11963	W 20041021

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
OTHER SOURCE(S): CASREACT 142:481826; MARPAT 142:481826  
GI



AB Title compds. I [R1 = H, alkyl, OH, CN, etc.; R2 = H, OH, alkyl, alkoxy, etc.; R3 = H, OH, alkyl, etc.; R4-5 = H, alkyl, etc.; R6-7 = H, alkyl; Ar1 = substituted Ph, pyridyl, etc.; n = 1-4; m = 0-4; p = 0-3; q = 1-3; t = 0-1; Z = O, CH2, bond] are prepared For instance, II is prepared in 6 steps from 2-(3-bromophenyl)ethanol, dihydropyran, benzyl 2-bromoethyl ether and (1R)-2-Amino-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanol as the acetate salt. Selected example compds. have pEC50 > 6 for the human  $\beta$ 2-receptor. I are useful for the treatment of asthma or chronic obstructive pulmonary disease (COPD).

IT 851857-85-7P 851857-86-8P 851857-89-1P  
 851857-90-4P 851857-91-5P 851857-92-6P  
 851857-93-7P 851857-94-8P 851857-95-9P  
 851857-96-0P 851858-07-6P 851858-08-7P  
 851858-09-8P 851858-10-1P 851858-11-2P  
 851858-12-3P 851858-13-4P 851858-14-5P  
 851858-15-6P 851858-16-7P 851858-17-8P  
 851858-18-9P 851858-19-0P 851858-20-3P  
 851858-21-4P 851858-22-5P 851858-23-6P  
 851858-24-7P 851858-25-8P 851858-26-9P  
 851858-27-0P 851858-28-1P 851858-29-2P  
 851858-30-5P 851858-38-3P 851858-39-4P  
 851858-41-8P 851858-42-9P 851858-43-0P  
 851858-44-1P 851858-45-2P 851858-46-3P  
 851858-47-4P 851858-48-5P 851858-49-6P  
 851858-50-9P 851858-51-0P 851858-52-1P  
 851858-53-2P 851858-54-3P 851858-57-6P  
 851858-58-7P 851858-59-8P 851858-60-1P  
 851858-87-2P 851858-88-3P 851858-89-4P  
 851858-90-7P 851858-97-4P 851858-98-5P  
 851858-99-6P 851859-00-2P 851859-01-3P  
 851859-02-4P 851859-08-0P 851859-09-1P  
 851859-10-4P 851859-11-5P 851859-12-6P  
 851859-13-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of Phenethanolamine derivs. as selective  $\beta$ 2-adrenoreceptor agonists for treatment of asthma and COPD)

RN 851857-85-7 CAPLUS

CN 1,3-Benzenedimethanol, 4-hydroxy- $\alpha$ 1-[[[2-[3-[[2-(phenylmethoxy)ethoxy]methyl]phenyl]ethyl]amino]methyl]-, ( $\alpha$ 1R)- (CA INDEX NAME)

Absolute stereochemistry.



10/923,271

RN 851857-86-8 CAPLUS


CN 1,3-Benzenedimethanol, 4-hydroxy- $\alpha$ 1-[[[2-[3-[[2-(phenylmethoxy)ethoxy]methyl]phenyl]ethyl]amino]methyl]-, acetate (1:1), ( $\alpha$ 1R)- (CA INDEX NAME)

CM 1

CRN 851857-85-7

CMF C27 H33 N O5


Absolute stereochemistry.



CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 851857-89-1 CAPLUS

CN 1,3-Benzenedimethanol, 4-hydroxy- $\alpha$ 1-[[[2-[3-[[3-(phenylpropoxy)methyl]phenyl]ethyl]amino]methyl]-, ( $\alpha$ 1R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 851857-90-4 CAPLUS

10/923,271


CN 1,3-Benzenedimethanol, 4-hydroxy- $\alpha$ 1-[[[2-[3-[(3-phenylpropoxy)methyl]phenyl]ethyl]amino]methyl]-, acetate (1:1), ( $\alpha$ 1R)- (CA INDEX NAME)

CM 1

CRN 851857-89-1

CMF C27 H33 N O4


Absolute stereochemistry.



CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 851857-91-5 CAPLUS

CN 1,3-Benzenedimethanol, 4-hydroxy- $\alpha$ 1-[[[2-[3-[(4-phenylbutoxy)methyl]phenyl]ethyl]amino]methyl]-, ( $\alpha$ 1R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 851857-92-6 CAPLUS

CN 1,3-Benzenedimethanol, 4-hydroxy- $\alpha$ 1-[[[2-[3-[(4-


10/923,271

phenylbutoxy)methyl]phenyl]ethyl]amino)methyl]-, acetate (1:1),  
( $\alpha$ 1R)- (CA INDEX NAME)

CM 1


CRN 851857-91-5  
CMF C28 H35 N O4

Absolute stereochemistry.




CM 2

CRN 64-19-7  
CMF C2 H4 O2



RN 851857-93-7 CAPLUS  
CN 1,3-Benzenedimethanol, 4-hydroxy- $\alpha$ 1-[[[2-[3-[[3-(phenylmethoxy)propoxy)methyl]phenyl]ethyl]amino)methyl]-, ( $\alpha$ 1R)-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 851857-94-8 CAPLUS  
CN 1,3-Benzenedimethanol, 4-hydroxy- $\alpha$ 1-[[[2-[3-[[3-(phenylmethoxy)propoxy)methyl]phenyl]ethyl]amino)methyl]-, acetate (1:1),

10/923,271


( $\alpha$ 1R)- (CA INDEX NAME)

CM 1

CRN 851857-93-7

CMF C28 H35 N O5


Absolute stereochemistry.



CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 851857-95-9 CAPLUS

CN 1,3-Benzenedimethanol, 4-hydroxy- $\alpha$ 1-[[[2-[4-[[2-(phenylmethoxy)ethoxy]methyl]phenyl]ethyl]amino]methyl]-, ( $\alpha$ 1R)-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 851857-96-0 CAPLUS

CN 1,3-Benzenedimethanol, 4-hydroxy- $\alpha$ 1-[[[2-[4-[[2-(phenylmethoxy)ethoxy]methyl]phenyl]ethyl]amino]methyl]-, acetate (1:1),  
( $\alpha$ 1R)- (CA INDEX NAME)




10/923,271

CM 1


CRN 851857-95-9  
CMF C27 H33 N O5

Absolute stereochemistry.



CM 2


CRN 64-19-7  
CMF C2 H4 O2



RN 851858-07-6 CAPLUS  
CN Benzenesulfonamide, 3-[4-[[3-[2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenyl]methoxy]butyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



—OH

RN 851858-08-7 CAPLUS

CN Formic acid, compd. with 3-[4-[[3-[2-[[ (2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenyl]methoxy]butyl]benzenesulfonamide (1:1) (CA INDEX NAME)


CM 1

CRN 851858-07-6

CMF C28 H36 N2 O6 S

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—OH

CM 2

CRN 64-18-6

CMF C H2 O2

O=CH—OH


10/923,271

RN 851858-09-8 CAPLUS

CN Benzonitrile, 3-[[2-[[3-[2-[[ (2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenyl]methoxy]ethoxy]methyl]-  
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

OH

RN 851858-10-1 CAPLUS


CN Formic acid, compd. with 3-[[2-[[3-[2-[[ (2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenyl]methoxy]ethoxy]methyl]benzo  
nitrile (1:1) (CA INDEX NAME)

CM 1

CRN 851858-09-8

CMF C28 H32 N2 O5


Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2



RN 851858-11-2 CAPLUS

CN 1,3-Benzenedimethanol,  $\alpha$ 1-[[[2-[3-[[2-[(2,6-dichlorophenyl)methoxy]ethoxy]methyl]phenyl]ethyl]amino]methyl]-4-hydroxy-, ( $\alpha$ 1R)- (CA INDEX NAME)

Absolute stereochemistry.




10/923,271

RN 851858-12-3 CAPLUS  
CN Formic acid, ( $\alpha$ 1R)-compd. with  
 $\alpha$ 1-[[[2-[3-[[2-[(2,6-  
dichlorophenyl)methoxy]ethoxy]methyl]phenyl]ethyl]amino]methyl]-4-hydroxy-  
1,3-benzenedimethanol (1:1) (CA INDEX NAME)

CM 1

CRN 851858-11-2  
CMF C27 H31 Cl2 N O5

Absolute stereochemistry.



CM 2


CRN 64-18-6  
CMF C H2 O2

O=CH-OH

RN 851858-13-4 CAPLUS  
CN 1,3-Benzenedimethanol,  $\alpha$ 1-[[[2-[3-[[2-[(3-  
fluorophenyl)methoxy]ethoxy]methyl]phenyl]ethyl]amino]methyl]-4-hydroxy-,  
( $\alpha$ 1R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



—OH


RN 851858-14-5 CAPLUS  
CN Formic acid, ( $\alpha$ 1R)-compd. with  
 $\alpha$ 1-[[[2-[3-[[2-[(3-fluorophenyl)methoxy]ethoxy]methyl]phenyl]ethyl]a  
mino]methyl]-4-hydroxy-1,3-benzenedimethanol (1:1) (CA INDEX NAME)

CM 1

CRN 851858-13-4  
CMF C27 H32 F N O5

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OH

CM 2

CRN 64-18-6  
CMF C H2 O2

10/923,271




RN 851858-15-6 CAPLUS

CN 1,3-Benzenedimethanol,  $\alpha$ 1-[[[2-[3-[[2-[(3,5-dimethylphenyl)methoxy]ethoxy)methyl]phenyl]ethyl]amino]methyl]-4-hydroxy-, ( $\alpha$ 1R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 851858-16-7 CAPLUS

CN Formic acid, ( $\alpha$ 1R)-compd. with  $\alpha$ 1-[[[2-[3-[[2-[(3,5-dimethylphenyl)methoxy]ethoxy)methyl]phenyl]ethyl]amino]methyl]-4-hydroxy-1,3-benzenedimethanol (1:1) (CA INDEX NAME)

CM 1


CRN 851858-15-6

CMF C29 H37 N O5

Absolute stereochemistry.

TOh

16/12/2009



—OH

CM 2

CRN 64-18-6

CMF C H2 O2

O=CH—OH


RN 851858-17-8 CAPLUS

CN 1,3-Benzenedimethanol, 4-hydroxy- $\alpha$ 1-[[[2-[3-[[2-[(3-methoxyphenyl)methoxy]ethoxy]methyl]phenyl]ethyl]amino]methyl]-, ( $\alpha$ 1R)- (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A



PAGE 1-B




RN 851858-18-9 CAPLUS  
 CN Formic acid, ( $\alpha$ 1R)-compd. with  
 4-hydroxy- $\alpha$ 1-[[[2-[3-[[2-[(3-  
 methoxyphenyl)methoxy]ethoxy]methyl]phenyl]ethyl]amino]methyl]-1,3-  
 benzenedimethanol (1:1) (CA INDEX NAME)


CM 1

CRN 851858-17-8  
 CMF C28 H35 N O6

Absolute stereochemistry.

PAGE 1-A






CM 2

CRN 64-18-6


CMF C H2 O2



RN 851858-19-0 CAPLUS

CN 1,3-Benzenedimethanol, 4-hydroxy- $\alpha$ 1-[[[2-[3-[[2-[[3-(trifluoromethoxy)phenyl]methoxy]ethoxy]methyl]phenyl]ethyl]amino]methyl]-, ( $\alpha$ 1R)- (CA INDEX NAME)

Absolute stereochemistry.




—OH

RN 851858-20-3 CAPLUS  
CN Formic acid, ( $\alpha$ 1R)-compd. with  
4-hydroxy- $\alpha$ 1-[[[2-[3-[[2-[[3-(trifluoromethoxy)phenyl]methoxy]ethoxy]methyl]phenyl]ethyl]amino]methyl]-1,3-benzenedimethanol (1:1) (CA INDEX NAME)

CM 1

CRN 851858-19-0  
CMF C28 H32 F3 N O6

Absolute stereochemistry.






CM 2

CRN 64-18-6


CMF C H2 O2



RN 851858-21-4 CAPLUS

CN 1,3-Benzenedimethanol, 4-hydroxy- $\alpha$ 1-[[[2-[3-[[4-(3-hydroxyphenyl)butoxy]methyl]phenyl]ethyl]amino]methyl]-, ( $\alpha$ 1R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 851858-22-5 CAPLUS

CN Formic acid, ( $\alpha$ 1R)-compd. with 4-hydroxy- $\alpha$ 1-[[[2-[3-[[4-(3-hydroxyphenyl)butoxy]methyl]phenyl]ethyl]amino]methyl]-1,3-benzenedimethanol (1:1) (CA INDEX NAME)


CM 1

CRN 851858-21-4

CMF C28 H35 N O5

Absolute stereochemistry.


10/923,271



CM 2

CRN 64-18-6


CMF C H2 O2



RN 851858-23-6 CAPLUS

CN Benzonitrile, 4-[3-[3-[2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenyl]methoxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 851858-24-7 CAPLUS

CN Formic acid, compd. with 4-[3-[3-[2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenyl]methoxy]propyl]benzonitrile (1:1) (CA INDEX NAME)


CM 1

CRN 851858-23-6

CMF C28 H32 N2 O4

Absolute stereochemistry.

10/923,271



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 851858-25-8 CAPLUS

CN Benzonitrile, 4-[4-[[3-[2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenyl]methoxy]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 851858-26-9 CAPLUS

CN Formic acid, compd. with 4-[4-[[3-[2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenyl]methoxy]butyl]benzonitrile (1:1) (CA INDEX NAME)


CM 1

CRN 851858-25-8

CMF C29 H34 N2 O4

Absolute stereochemistry.

10/923,271



CM 2

CRN 64-18-6


CMF C H2 O2

$O=CH-OH$

RN 851858-27-0 CAPLUS

CN Benzonitrile, 3-[3-[3-[2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenyl]methoxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 851858-28-1 CAPLUS

CN Formic acid, compd. with 3-[3-[3-[2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenyl]methoxy]propyl]benzonitrile (1:1) (CA INDEX NAME)


CM 1

CRN 851858-27-0

CMF C28 H32 N2 O4

Absolute stereochemistry.


10/923,271



CM 2

CRN 64-18-6

CMF C H2 O2




RN 851858-29-2 CAPLUS

CN 1,3-Benzenedimethanol, 4-hydroxy- $\alpha$ 1-[[[2-[3-[3-[4-(methylsulfonyl)phenyl]propoxy]methyl]phenyl]ethyl]amino]methyl]-, ( $\alpha$ 1R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 851858-30-5 CAPLUS

CN Formic acid, ( $\alpha$ 1R)-compd. with 4-hydroxy- $\alpha$ 1-[[[2-[3-[3-[4-

TOb

16/12/2009



10/923,271

(methylsulfonyl)phenyl]propoxy)methyl]phenyl]ethyl]amino)methyl]-1,3-benzenedimethanol (1:1) (CA INDEX NAME)


CM 1

CRN 851858-29-2

CMF C28 H35 N O6 S

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



CM 2

CRN 64-18-6

CMF C H2 O2




RN 851858-38-3 CAPLUS

CN 1,3-Benzenedimethanol, 4-hydroxy- $\alpha$ 1-[[[2-[3-[[3-(2-hydroxyphenyl)propoxy)methyl]phenyl]ethyl]amino)methyl]-, ( $\alpha$ 1R)- (CA INDEX NAME)

Absolute stereochemistry.

10/923,271




RN 851858-39-4 CAPLUS  
CN Formic acid, (α1R)-compd. with  
4-hydroxy-α1-[[[2-[3-[[3-(2-  
hydroxyphenyl)propoxy]methyl]phenyl]ethyl]amino]methyl]-1,3-  
benzenedimethanol (1:1) (CA INDEX NAME)

CM 1

CRN 851858-38-3  
CMF C27 H33 N O5

Absolute stereochemistry.



CM 2


CRN 64-18-6  
CMF C H2 O2

O=CH-OH

RN 851858-41-8 CAPLUS  
CN 1,3-Benzenedimethanol, 4-hydroxy-α1-[[[2-[3-[[3-(3-  
hydroxyphenyl)propoxy]methyl]phenyl]ethyl]amino]methyl]-, (α1R)-  
(CA INDEX NAME)

Absolute stereochemistry.

10/923,271




RN 851858-42-9 CAPLUS  
CN Formic acid, (α1R)-compd. with  
4-hydroxy-α1-[[[2-[3-[[3-(3-  
hydroxyphenyl)propoxy]methyl]phenyl]ethyl]amino]methyl]-1,3-  
benzenedimethanol (1:1) (CA INDEX NAME)

CM 1

CRN 851858-41-8  
CMF C27 H33 N O5

Absolute stereochemistry.



CM 2


CRN 64-18-6  
CMF C H2 O2

O=CH-OH


RN 851858-43-0 CAPLUS  
CN 1,3-Benzenedimethanol, α1-[[[2-[3-[[4-[4-  
(cyclopentylsulfonyl)phenyl]butoxy]methyl]phenyl]ethyl]amino]methyl]-4-  
hydroxy-, (α1R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 851858-44-1 CAPLUS  
 CN Formic acid, ( $\alpha$ 1R)-compd. with  
 $\alpha$ 1-[[[2-[3-[[4-[4-(cyclopentylsulfonyl)phenyl]butoxy]methyl]phenyl]e  
 thyl]amino]methyl]-4-hydroxy-1,3-benzenedimethanol (1:1) (CA INDEX NAME)


CM 1

CRN 851858-43-0  
 CMF C33 H43 N O6 S

Absolute stereochemistry.

PAGE 1-A






CM 2

CRN 64-18-6



CMF C H2 O2



RN 851858-45-2 CAPLUS

CN 1,3-Benzenedimethanol,  $\alpha$ 1-[[[2-[3-[3-[4-(cyclopentylsulfonyl)phenyl]propoxy]methyl]phenyl]ethyl]amino]methyl]-4-hydroxy-, ( $\alpha$ 1R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 851858-46-3 CAPLUS

CN Formic acid, ( $\alpha$ 1R)-compd. with  
 $\alpha$ 1-[[[2-[3-[3-[4-(cyclopentylsulfonyl)phenyl]propoxy]methyl]phenyl]

10/923,271

ethyl]amino]methyl]-4-hydroxy-1,3-benzenedimethanol (1:1) (CA INDEX NAME)


CM 1

CRN 851858-45-2


CMF C32 H41 N O6 S

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH


RN 851858-47-4 CAPLUS

CN 1,3-Benzenedimethanol,  $\alpha$ 1-[[[2-[3-[3-[3-(cyclopentylsulfonyl)phenyl]propoxy]methyl]phenyl]ethyl]amino]methyl]-4-hydroxy-, ( $\alpha$ 1R)- (CA INDEX NAME)


Absolute stereochemistry.

10/923,271

PAGE 1-A




PAGE 1-B




RN 851858-48-5 CAPLUS  
CN Formic acid, ( $\alpha$ 1R)-compd. with  
 $\alpha$ 1-[[[2-[3-[[3-[3-(cyclopentylsulfonyl)phenyl]propoxy]methyl]phenyl]  
ethyl]amino]methyl]-4-hydroxy-1,3-benzenedimethanol (1:1) (CA INDEX NAME)  
CM 1  
CRN 851858-47-4  
CMF C32 H41 N O6 S

Absolute stereochemistry.

PAGE 1-A






CM 2

CRN 64-18-6


CMF C H2 O2



RN 851858-49-6 CAPLUS

CN 1,3-Benzenedimethanol, 4-hydroxy- $\alpha$ 1-[[[2-[3-[[2-[(3-hydroxyphenyl)methoxy]ethoxy]methyl]phenyl]ethyl]amino]methyl]-, ( $\alpha$ 1R)- (CA INDEX NAME)

Absolute stereochemistry.





10/923,271


RN 851858-50-9 CAPLUS  
CN Formic acid, ( $\alpha$ 1R)-compd. with  
4-hydroxy- $\alpha$ 1-[[[2-[3-[[2-[(3-  
hydroxyphenyl)methoxy]ethoxy)methyl]phenyl]ethyl]amino]methyl]-1,3-  
benzenedimethanol (1:1) (CA INDEX NAME)

CM 1

CRN 851858-49-6  
CMF C27 H33 N O6

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B





CM 2

CRN 64-18-6  
CMF C H2 O2



RN 851858-51-0 CAPLUS  
CN 1,3-Benzenedimethanol,  $\alpha$ 1-[[[2-[3-[[2-[[3-  
(cyclopentylsulfonyl)phenyl]methoxy]ethoxy)methyl]phenyl]ethyl]amino]methy  
l]-4-hydroxy-, ( $\alpha$ 1R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851858-52-1 CAPLUS  
 CN Formic acid, ( $\alpha$ 1R)-compd. with  
 $\alpha$ 1-[[[2-[3-[[2-[[3-(cyclopentylsulfonyl)phenyl]methoxy]ethoxy]methyl  
 ]phenyl]ethyl]amino]methyl]-4-hydroxy-1,3-benzenedimethanol (1:1) (CA  
 INDEX NAME)

CM 1


CRN 851858-51-0  
 CMF C32 H41 N O7 S

Absolute stereochemistry.



10/923,271

PAGE 1-B



CM 2

CRN 64-18-6

CMF C H2 O2


O=CH-OH

RN 851858-53-2 CAPLUS


CN 1,3-Benzenedimethanol,  $\alpha$ 1-[[[2-[3-[2-[3-(cyclopentylsulfinyl)phenyl]methoxy]ethoxy]methyl]phenyl]ethyl]amino]methyl]-4-hydroxy-, ( $\alpha$ 1R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 851858-54-3 CAPLUS

CN Formic acid, ( $\alpha$ 1R)-compd. with

TOh

16/12/2009

10/923,271

$\alpha$ 1-[[[2-[3-[[2-[[3-(cyclopentylsulfinyl)phenyl]methoxy]ethoxy]methyl]  
phenyl]ethyl]amino]methyl]-4-hydroxy-1,3-benzenedimethanol (1:1) (CA  
INDEX NAME)


CM 1

CRN 851858-53-2


CMF C32 H41 N O6 S

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



CM 2

CRN 64-18-6

CMF C H2 O2


O=CH-OH

RN 851858-57-6 CAPLUS


CN 1,3-Benzenedimethanol,  $\alpha$ 1-[[[2-[3-[[4-[3-(cyclopentylsulfinyl)phenyl]butoxy]methyl]phenyl]ethyl]amino]methyl]-4-hydroxy-, ( $\alpha$ 1R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 851858-58-7 CAPLUS

CN Formic acid, ( $\alpha$ 1R)-compd. with  
 $\alpha$ 1-[[[2-[3-[[4-[3-(cyclopentylsulfinyl)phenyl]butoxy]methyl]phenyl]e  
 thyl]amino]methyl]-4-hydroxy-1,3-benzenedimethanol (1:1) (CA INDEX NAME)


CM 1


CRN 851858-57-6

CMF C33 H43 N O5 S

Absolute stereochemistry.

PAGE 1-A






CM 2

CRN 64-18-6


CMF C H2 O2



RN 851858-59-8 CAPLUS

CN Benzonitrile, 3-[4-[[3-[2-[[ (2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenyl]methoxy]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 851858-60-1 CAPLUS

CN Formic acid, compd. with 3-[4-[[3-[2-[[ (2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenyl]methoxy]butyl]benzonitrile (1:1) (CA INDEX NAME)


CM 1

CRN 851858-59-8

CMF C29 H34 N2 O4

Absolute stereochemistry.


10/923,271



CM 2

CRN 64-18-6

CMF C H2 O2




RN 851858-87-2 CAPLUS

CN Benzamide, 3-[4-[[3-[2-[[ (2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenyl]methoxy]butyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 851858-88-3 CAPLUS

TOh

16/12/2009

10/923,271

CN Formic acid, compd. with 3-[4-[[3-[2-[[ (2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenyl]methoxy]butyl]benzamide (1:1) (CA INDEX NAME)


CM 1

CRN 851858-87-2

CMF C29 H36 N2 O5

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



CM 2

CRN 64-18-6

CMF C H2 O2



RN 851858-89-4 CAPLUS

CN Benzamide, 3-[[2-[[3-[2-[[ (2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenyl]methoxy]ethoxy]methyl]- (CA INDEX NAME)


Absolute stereochemistry.

TOh


16/12/2009



PAGE 1-A



PAGE 1-B



RN 851858-90-7 CAPLUS

CN Formic acid, compd. with 3-[[2-[[3-[2-[[[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenyl]methoxy]ethoxy]methyl]benzamide (1:1) (CA INDEX NAME)


CM 1

CRN 851858-89-4

CMF C28 H34 N2 O6


Absolute stereochemistry.

PAGE 1-A



10/923,271


PAGE 1-B



CM 2

CRN 64-18-6

CMF C H2 O2




RN 851858-97-4 CAPLUS

CN Benzenesulfonamide, 3-[3-[[3-[2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenyl]methoxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 851858-98-5 CAPLUS

TOb

16/12/2009

10/923,271

CN Formic acid, compd. with 3-[3-[[3-[2-[[ (2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenyl]methoxy]propyl]benzenesulfonamide (1:1) (CA INDEX NAME)


CM 1

CRN 851858-97-4

CMF C27 H34 N2 O6 S

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



CM 2

CRN 64-18-6

CMF C H2 O2




RN 851858-99-6 CAPLUS

CN 1,3-Benzenedimethanol,  $\alpha$ 1-[[[2-[3-[[4-(2,6-dichlorophenyl)butoxy]methyl]phenyl]ethyl]amino]methyl]-4-hydroxy-, ( $\alpha$ 1R)- (CA INDEX NAME)

Absolute stereochemistry.

10/923,271




RN 851859-00-2 CAPLUS  
CN Formic acid, ( $\alpha$ 1R)-compd. with  
 $\alpha$ 1-[[[2-[3-[[4-(2,6-  
dichlorophenyl)butoxy]methyl]phenyl]ethyl]amino]methyl]-4-hydroxy-1,3-  
benzenedimethanol (1:1) (CA INDEX NAME)

CM 1

CRN 851858-99-6  
CMF C28 H33 Cl2 N O4

Absolute stereochemistry.



CM 2


CRN 64-18-6  
CMF C H2 O2

O=CH-OH


RN 851859-01-3 CAPLUS  
CN Urea, N-[3-[4-[[3-[2-[[ (2R)-2-hydroxy-2-[4-hydroxy-3-  
(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenyl]methoxy]butyl]phenyl]- (CA  
INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 851859-02-4 CAPLUS

CN Formic acid, compd. with N-[3-[4-[[3-[2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenyl]methoxy]butyl]phenyl]urea (1:1) (CA INDEX NAME)


CM 1

CRN 851859-01-3

CMF C29 H37 N3 O5


Absolute stereochemistry.

PAGE 1-A



10/923,271

PAGE 1-B



CM 2

CRN 64-18-6

CMF C H2 O2


O=CH-OH

RN 851859-08-0 CAPLUS


CN 1,3-Benzenedimethanol,  $\alpha$ 1-[[[2-[3-[[4-[3-(cyclopentylsulfonyl)phenyl]butoxy]methyl]phenyl]ethyl]amino]methyl]-4-hydroxy-, ( $\alpha$ 1R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 851859-09-1 CAPLUS

CN Formic acid, ( $\alpha$ 1R)-compd. with

TOh

16/12/2009

10/923,271



$\alpha$ 1-[[[2-[3-[[4-[3-(cyclopentylsulfonyl)phenyl]butoxy)methyl]phenyl]ethyl]amino)methyl]-4-hydroxy-1,3-benzenedimethanol (1:1) (CA INDEX NAME)

CM 1

CRN 851859-08-0

CMF C33 H43 N O6 S

Absolute stereochemistry.



CM 2

CRN 64-18-6

CMF C H2 O2


$\text{O}=\text{CH}-\text{OH}$

RN 851859-10-4 CAPLUS

CN 1,3-Benzenedimethanol, 4-hydroxy- $\alpha$ 1-[[[2-[3-[[4-[3-(methylsulfonyl)phenyl]butoxy)methyl]phenyl]ethyl]amino)methyl]-, ( $\alpha$ 1R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—OH


RN 851859-11-5 CAPLUS  
 CN Formic acid, ( $\alpha$ 1R)-compd. with  
 4-hydroxy- $\alpha$ 1-[[[2-[3-[[4-[3-(  
 (methylsulfonyl)phenyl]butoxy]methyl]phenyl]ethyl]amino]methyl]-1,3-  
 benzenedimethanol (1:1) (CA INDEX NAME)

CM 1

CRN 851859-10-4  
 CMF C29 H37 N O6 S

Absolute stereochemistry.

PAGE 1-A







CM 2

CRN 64-18-6


CMF C H2 O2



RN 851859-12-6 CAPLUS

CN 1,3-Benzenedimethanol,  $\alpha$ 1-[[[2-[3-[3-(2,6-dichlorophenyl)propoxy]methyl]phenyl]ethyl]amino]methyl]-4-hydroxy-, ( $\alpha$ 1R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 851859-13-7 CAPLUS

CN Formic acid, ( $\alpha$ 1R)-compd. with  $\alpha$ 1-[[[2-[3-[3-(2,6-dichlorophenyl)propoxy]methyl]phenyl]ethyl]amino]methyl]-4-hydroxy-1,3-benzenedimethanol (1:1) (CA INDEX NAME)


CM 1

CRN 851859-12-6

CMF C27 H31 Cl2 N O4

Absolute stereochemistry.

10/923,271



CM 2


CRN 64-18-6

CMF C H2 O2

O=CH-OH

IT 851859-19-3P 851859-25-1P 851859-28-4P  
851859-31-9P 851859-35-3P 851859-87-5P,  
(1R)-2-[[2-(3-[[3-(2,6-Dichlorophenyl)propoxy)methyl]phenyl)ethyl]amino]-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanol  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of Phenethanolamine derivs. as selective  $\beta$ 2-adrenoreceptor agonists for treatment of asthma and COPD)  
RN 851859-19-3 CAPLUS  
CN 4H-1,3-Benzodioxin-6-methanol, 2,2-dimethyl- $\alpha$ -[[[2-[3-[[2-(phenylmethoxy)ethoxy)methyl]phenyl]ethyl]amino]methyl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851859-25-1 CAPLUS  
CN 4H-1,3-Benzodioxin-6-methanol, 2,2-dimethyl- $\alpha$ -[[[2-[3-[[3-phenylpropoxy)methyl]phenyl]ethyl]amino]methyl]-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.


10/923,271



RN 851859-28-4 CAPLUS

CN 4H-1,3-Benzodioxin-6-methanol, 2,2-dimethyl- $\alpha$ -[[[2-[3-[(4-phenylbutoxy)methyl]phenyl]ethyl]amino]methyl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851859-31-9 CAPLUS

CN 4H-1,3-Benzodioxin-6-methanol, 2,2-dimethyl- $\alpha$ -[[[2-[3-[[3-(phenylmethoxy)propoxy]methyl]phenyl]ethyl]amino]methyl]-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851859-35-3 CAPLUS

CN 4H-1,3-Benzodioxin-6-methanol, 2,2-dimethyl- $\alpha$ -[[[2-[4-[[2-(phenylmethoxy)ethoxy]methyl]phenyl]ethyl]amino]methyl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.

10/923,271



RN 851859-87-5 CAPLUS  
CN 4H-1,3-Benzodioxin-6-methanol,  $\alpha$ -[[[2-[3-[[3-(2,6-dichlorophenyl)propoxy]methyl]phenyl]ethyl]amino]methyl]-2,2-dimethyl-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)  
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>